{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:33:07Z","timestamp":1793093587501,"version":"4.5.0"},"reference-count":177,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The advent of personalized medicine has revolutionized the whole approach to the management of asthma, representing the essential basis for future developments. The cornerstones of personalized medicine are the highest precision in diagnosis, individualized prediction of disease evolution, and patient-tailored treatment. To this aim, enormous efforts have been established to discover biomarkers able to predict patients' phenotypes according to clinical, functional, and bio-humoral traits. Biomarkers are objectively measured characteristics used as indicators of biological or pathogenic processes or clinical responses to specific therapeutic interventions. The diagnosis of type-2 asthma, prediction of response to type-2 targeted treatments, and evaluation of the risk of exacerbation and lung function impairment have been associated with biomarkers detectable either in peripheral blood or in airway samples. The surrogate nature of serum biomarkers, set up to be less invasive than sputum analysis or bronchial biopsies, has shown several limits concerning their clinical applicability. Routinely used biomarkers, like peripheral eosinophilia, total IgE, or exhaled nitric oxide, result, even when combined, to be not completely satisfactory in segregating different type-2 asthma phenotypes, particularly in the context of severe asthma where the choice among different biologics is compelling. Moreover, the type-2 low fraction of patients is not only an orphan of biological treatments but is at risk of being misdiagnosed due to the low negative predictive value of type-2 high biomarkers. Sputum inflammatory cell analysis, considered the highest specific biomarker in discriminating eosinophilic inflammation in asthma, and therefore elected as the gold standard in clinical trials and research models, demonstrated many limits in clinical applicability. Many factors may influence the measure of these biomarkers, such as corticosteroid intake, comorbidities, and environmental exposures or habits. Not least, biomarkers variability over time is a confounding factor leading to wrong clinical choices. In this narrative review, we try to explore many aspects concerning the role of routinely used biomarkers in asthma, applying a critical view over the \u201cstate of the art\u201d and contemporarily offering an overview of the most recent evidence in this field.<\/jats:p>","DOI":"10.3389\/fmed.2022.969243","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T04:58:11Z","timestamp":1665377891000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":84,"title":["Critical evaluation of asthma biomarkers in clinical practice"],"prefix":"10.3389","volume":"9","author":[{"given":"Giuseppe","family":"Guida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Bagnasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitina","family":"Carriero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bertolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio Luigi Massimo","family":"Ricciardolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Nicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Brussino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Walter","family":"Canonica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Heffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5334\/aogh.2412","article-title":"The Global Impact of Asthma in Adult Populations","volume":"85","author":"Enilari","year":"2019","journal-title":"Ann Glob Health."},{"key":"B2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/ACI.0000000000000416","article-title":"Asthma: Personalized and precision medicine","volume":"18","author":"Canonica","year":"2018","journal-title":"Curr Opin Allergy Clin Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2147\/BTT.S29976","article-title":"Maitland-van der Zee AH, Koenderman L. Clinical utility of asthma biomarkers: From bench to bedside","volume":"7","author":"Vijverberg","year":"2013","journal-title":"Biologics."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2019.05.031","article-title":"Phenotypes and endotypes of adult asthma: Moving toward precision medicine","volume":"144","author":"Kaur","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1016\/j.jaip.2021.02.059","article-title":"Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry","volume":"9","author":"Denton","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e934475","DOI":"10.12659\/MSM.934475","article-title":"Editorial: Review Articles, Systematic Reviews, Meta-Analysis, and the Updated Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 Guidelines","volume":"27","author":"Parums","year":"2021","journal-title":"Med Sci Monit."},{"key":"B7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1081-1206(10)61388-9","article-title":"Determinants of asthma and its clinical course","volume":"93","author":"Chipps","year":"2004","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B8","unstructured":"Global Strategy for Asthma Management Prevention.2022"},{"key":"B9","doi-asserted-by":"publisher","first-page":"100606","DOI":"10.1016\/j.waojou.2021.100606","article-title":"Severe asthma: one disease and multiple definitions","volume":"14","author":"Bagnasco","year":"2021","journal-title":"World Allergy Organ J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/sj.bdj.2013.482","article-title":"Difficult-to-treat & severe asthma in adolescent and adult patients - diagnosis and management","volume":"214","author":"Darcey","year":"2019","journal-title":"Glob Initiat Asthma."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/all.13370","article-title":"Comorbid \u201ctreatable traits\u201d in difficult asthma: current evidence and clinical evaluation","volume":"73","author":"Tay","year":"2018","journal-title":"Allergy."},{"key":"B13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2500\/aap.2020.41.200015","article-title":"Biologics for oral corticosteroid-dependent asthma","volume":"41","author":"Yilmaz","year":"2020","journal-title":"Allergy Asthma Proc."},{"key":"B14","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/nm.2678","article-title":"Asthma phenotypes: The evolution from clinical to molecular approaches","volume":"18","author":"Wenzel","year":"2012","journal-title":"Nat Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding asthma phenotypes, endotypes, and mechanisms of disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin Rev Allergy Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.anai.2016.05.016","article-title":"Characterization of asthma endotypes: implications for therapy","volume":"117","author":"Stokes","year":"2016","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1067\/mai.2001.114883","article-title":"TH2 cytokine-associated transcription factors in atopic and nonatopic asthma: Evidence for differential signal transducer and activator of transcription 6 expression","volume":"107","author":"Christodoulopoulos","year":"2001","journal-title":"J Allergy Clin Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.alit.2017.08.011","article-title":"Role of airway epithelial barrier dysfunction in pathogenesis of asthma","volume":"67","author":"Gon","year":"2018","journal-title":"Allergol Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.coi.2020.10.002","article-title":"Mechanisms of non-type 2 asthma","volume":"66","author":"Hudey","year":"2020","journal-title":"Curr Opin Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/joim.12382","article-title":"Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies","volume":"279","author":"Chung","year":"2016","journal-title":"J Intern Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12948-015-0027-7","article-title":"Biomarkers and severe asthma: a critical appraisal","volume":"13","author":"Chiappori","year":"2015","journal-title":"Clin Mol Allergy."},{"key":"B22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/cea.12881","article-title":"The current and future role of biomarkers in type 2 cytokine-mediated asthma management","volume":"47","author":"Pavord","year":"2017","journal-title":"Clin Exp Allergy."},{"key":"B23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000504847","article-title":"The cellular functions of eosinophils: Collegium Internationale Allergologicum (CIA) Update 2020","volume":"181","author":"Simon","year":"2020","journal-title":"Int Arch Allergy Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1172\/JCI111411","article-title":"Eosinophil-mediated injury to lung parenchymal cells and interstitial matrix. A possible role for eosinophils in chronic inflammatory disorders of the lower respiratory tract","volume":"74","author":"Davis","year":"1984","journal-title":"J Clin Invest."},{"key":"B25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1164\/rccm.200905-0736OC","article-title":"Eosinophils are dispensable for allergic remodeling and immunity in a model of house dust mite-induced airway disease","volume":"183","author":"Fattouh","year":"2011","journal-title":"Am J Respir Crit Care Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJM199010113231505","article-title":"Eosinophilic inflammation in asthma","volume":"323","author":"Bousquet","year":"1990","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1172\/JCI85664","article-title":"Lung-resident eosinophils represent a distinct regulatory eosinophil subset","volume":"126","author":"Mesnil","year":"2016","journal-title":"J Clin Invest."},{"key":"B28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.anai.2018.02.031","article-title":"The eosinophil: For better or worse, in sickness and in health","volume":"121","author":"Bochner","year":"2018","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/j.1365-2222.1995.tb00024.x","article-title":"Peripheral eosinophil counts as a marker of disease activity in intrinsic and extrinsic asthma","volume":"25","author":"Ulrik","year":"1995","journal-title":"Clin Exp Allergy."},{"key":"B30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-2466-13-11","article-title":"Distribution of sputum cellular phenotype in a large asthma cohort: Predicting factors for eosinophilic vs neutrophilic inflammation","volume":"13","author":"Schleich","year":"2013","journal-title":"BMC Pulm Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/thoraxjnl-2014-205634","article-title":"External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma","volume":"70","author":"Wagener","year":"2015","journal-title":"Thorax."},{"key":"B32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jaci.2013.03.044","article-title":"Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects","volume":"132","author":"Hastie","year":"2013","journal-title":"J Allergy Clin Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13223-018-0248-7","article-title":"Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma","volume":"14","author":"Gao","year":"2018","journal-title":"Allergy Asthma Clin Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"100547","DOI":"10.1016\/j.waojou.2021.100547","article-title":"Variability of Type 2 inflammatory markers guiding biologic therapy of severe asthma: a 5-year retrospective study from a single tertiary hospital","volume":"14","author":"Li","year":"2021","journal-title":"World Allergy Organ J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S2213-2600(15)00050-8","article-title":"Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis","volume":"3","author":"Korevaar","year":"2015","journal-title":"Lancet Respir Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1183\/09031936.00012415","article-title":"Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes","volume":"46","author":"Westerhof","year":"2015","journal-title":"Eur Respir J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody, vs. placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N Engl J Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"176","author":"Flood-Page","year":"2007","journal-title":"Am J Respir Crit Care Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02770903.2021.2008431","article-title":"Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review","volume":"19","author":"Israel","year":"2021","journal-title":"J Asthma."},{"key":"B45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2147\/JAA.S236609","article-title":"Real-world effectiveness of mepolizumab in patients with severe asthma: an examination of exacerbations and costs","volume":"13","author":"Llanos","year":"2020","journal-title":"J Asthma Allergy."},{"key":"B46","doi-asserted-by":"publisher","first-page":"106491","DOI":"10.1016\/j.rmed.2021.106491","article-title":"Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: a real-world retrospective pilot study","volume":"185","author":"Crimi","year":"2021","journal-title":"Respir Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jaci.2010.04.005","article-title":"Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti\u2013IL-5 receptor \u03b1 antibody, in a phase I study of subjects with mild asthma","volume":"125","author":"Busse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","article-title":"Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia","volume":"132","author":"Laviolette","year":"2013","journal-title":"J Allergy Clin Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1080\/03007995.2017.1347091","article-title":"The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies","volume":"33","author":"Goldman","year":"2017","journal-title":"Curr Med Res Opin."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1800936","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur Respir J."},{"key":"B53","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1164\/ajrccm.164.supplement_1.2103024","article-title":"The role of immunoglobulin E in allergy and asthma","volume":"164","author":"Platts-Mills","year":"2001","journal-title":"Am J Respir Crit Care Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.pharmthera.2006.07.003","article-title":"Immunoglobulin E: Role in asthma and allergic disease: lessons from the clinic","volume":"113","author":"Owen","year":"2007","journal-title":"Pharmacol Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"103","DOI":"10.23822\/EurAnnACI.1764-1489.196","article-title":"Severe asthma management in the era of biologics: insights of the italian registry on severe asthma (irsa)","volume":"53","author":"Bil\u00f2","year":"2021","journal-title":"Eur Ann Allergy Clin Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1800938","DOI":"10.1183\/13993003.00938-2018","article-title":"\u201cT2-high\u201d in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin","volume":"53","author":"Pavlidis","year":"2019","journal-title":"Eur Respir J."},{"key":"B57","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2-driven inflammation defines major subphenotypes of asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am J Respir Crit Care Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jaip.2020.09.051","article-title":"Porsbjerg C. The prevalence of subtypes of type 2 inflammation in an unselected population of patients with severe asthma","volume":"9","author":"Fr\u00f8ssing","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/imj.13166","article-title":"Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry","volume":"46","author":"Gibson","year":"2016","journal-title":"Intern Med J."},{"key":"B60","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1136\/thoraxjnl-2017-210017","article-title":"Duration of the efficacy of omalizumab after treatment discontinuation in \u201creal life\u201d severe asthma","volume":"73","author":"Del Carmen Vennera","year":"2018","journal-title":"Thorax."},{"key":"B61","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jaci.2016.08.054","article-title":"A randomized multicenter study evaluating Xolair persistence of response after long-term therapy","volume":"140","author":"Ledford","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jaip.2019.08.050","article-title":"Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma","volume":"8","author":"Corren","year":"2020","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00000302","article-title":"Sputum induction","author":"Paggiaro","year":"2002","journal-title":"Eur Respir J Suppl."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1164\/ajrccm.162.3.9908057","article-title":"Induced Sputum Cellularity","volume":"162","author":"Spanevello","year":"2000","journal-title":"Am J Respir Crit Care Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1164\/ajrccm.161.2.9903097","article-title":"Induced sputum cell counts in healthy adults","volume":"161","author":"Belda","year":"2000","journal-title":"Am J Respir Crit Care Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1440-1843.2006.00784.x","article-title":"Inflammatory subtypes in asthma: assessment and identification using induced sputum","volume":"11","author":"Simpson","year":"2006","journal-title":"Respirology."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.jaci.2010.02.008","article-title":"Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes","volume":"125","author":"Hastie","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12890-016-0208-2","article-title":"Detailed analysis of sputum and systemic inflammation in asthma phenotypes: are paucigranulocytic asthmatics really non-inflammatory?","volume":"16","author":"Demarche","year":"2016","journal-title":"BMC Pulm Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1111\/all.13184","article-title":"Clinical, functional and inflammatory characteristics in patients with paucigranulocytic stable asthma: Comparison with different sputum phenotypes","volume":"72","author":"Ntontsi","year":"2017","journal-title":"Allergy."},{"key":"B70","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000245899","article-title":"Assessment and reproducibility of non-eosinophilic asthma using induced sputum","volume":"79","author":"Simpson","year":"2010","journal-title":"Respiration."},{"key":"B71","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1164\/rccm.201109-1640OC","article-title":"A large subgroup of mild-to-moderate asthma is persistently noneosinophilic","volume":"185","author":"McGrath","year":"2012","journal-title":"Am J Respir Crit Care Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/all.12445","article-title":"Stability of phenotypes defined by physiological variables and biomarkers in adults with asthma","volume":"69","author":"Kupczyk","year":"2014","journal-title":"Allergy."},{"key":"B73","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/s12890-021-01722-0","article-title":"Distribution of inflammatory phenotypes among patients with asthma in Jilin Province, China: a cross-sectional study","volume":"21","author":"Shi","year":"2021","journal-title":"BMC Pulm Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1165\/ajrcmb.12.5.7742012","article-title":"Phenotype of cells expressing mRNA for TH2-type (interleukin 4 and interleukin 5) and TH1-type (interleukin 2 and interferon gamma) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects","volume":"12","author":"Ying","year":"1995","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/PL00007606","article-title":"Airway eosinophilic inflammation and bronchial hyperresponsiveness after allergen inhalation challenge in asthma","volume":"176","author":"Oddera","year":"1998","journal-title":"Lung."},{"key":"B76","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1164\/ajrccm.160.2.9809130","article-title":"Kinetics of allergen-induced airway eosinophilic cytokine production and airway inflammation","volume":"160","author":"Gauvreau","year":"1999","journal-title":"Am J Respir Crit Care Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1164\/ajrccm.157.1.9703002","article-title":"Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma","volume":"157","author":"Crimi","year":"1998","journal-title":"Am J Respir Crit Care Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.rmed.2005.04.026","article-title":"Clinical features and airway inflammation in mild asthma vs. asymptomatic airway hyperresponsiveness","volume":"100","author":"Boulet","year":"2006","journal-title":"Respir Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1034\/j.1398-9995.2002.23608.x","article-title":"Sputum eosinophil count in a large population of patients with mild to moderate steroid-naive asthma: distribution and relationship with methacholine bronchial hyperresponsiveness","volume":"57","author":"Louis","year":"2002","journal-title":"Allergy."},{"key":"B80","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/thx.53.2.91","article-title":"Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma","volume":"53","author":"Jatakanon","year":"1998","journal-title":"Thorax."},{"key":"B81","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1183\/09031936.03.00261903","article-title":"cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma","volume":"22","year":"2003","journal-title":"Eur Respir J."},{"key":"B82","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.rmed.2012.12.015","article-title":"Discordance between asthma control clinical, physiological and inflammatory parameters in mild asthma","volume":"107","author":"Boulay","year":"2013","journal-title":"Respir Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1183\/09031936.02.00017502","article-title":"Assessment and evaluation of symptomatic steroid-naive asthmatics without sputum eosinophilia and their response to inhaled corticosteroids","volume":"20","author":"Godon","year":"2002","journal-title":"Eur Respir J."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1183\/13993003.00779-2015","article-title":"Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort","volume":"46","author":"Shaw","year":"2015","journal-title":"Eur Respir J."},{"key":"B85","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1136\/thx.54.5.403","article-title":"Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma","volume":"54","author":"van Rensen","year":"1999","journal-title":"Thorax."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1378\/chest.119.4.1011","article-title":"Mild exacerbations and eosinophilic inflammation in patients with stable, well-controlled asthma after 1 year of follow-up","volume":"119","author":"Belda","year":"2001","journal-title":"Chest."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1046\/j.1365-2222.2002.01412.x","article-title":"Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma","volume":"32","author":"Meijer","year":"2002","journal-title":"Clin Exp Allergy."},{"key":"B88","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jaci.2004.12.1129","article-title":"Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids","volume":"115","author":"Deykin","year":"2005","journal-title":"J Allergy Clin Immunol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","article-title":"Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial","volume":"360","author":"Green","year":"2002","journal-title":"Lancet."},{"key":"B90","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1183\/09031936.06.00137704","article-title":"Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations","volume":"27","author":"Jayaram","year":"2006","journal-title":"Eur Respir J."},{"key":"B91","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/thx.2010.135574","article-title":"A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils)","volume":"67","author":"Petsky","year":"2012","journal-title":"Thorax."},{"key":"B92","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S0091-6749(99)70402-1","article-title":"Sputum eosinophil count to assess compliance with corticosteroid therapy in asthma","volume":"104","author":"Parameswaran","year":"1999","journal-title":"J Allergy Clin Immunol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1136\/thx.50.10.1057","article-title":"Exacerbations of asthma without sputum eosinophilia","volume":"50","author":"Turner","year":"1995","journal-title":"Thorax."},{"key":"B94","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1136\/thorax.57.7.643","article-title":"Non-eosinophilic asthma: importance and possible mechanisms","volume":"57","author":"Douwes","year":"2002","journal-title":"Thorax."},{"key":"B95","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/S0140-6736(99)01813-9","article-title":"Non-eosinophilic corticosteroid unresponsive asthma","volume":"353","author":"Pavord","year":"1999","journal-title":"Lancet."},{"key":"B96","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/thx.2009.126722","article-title":"Effects of steroid therapy on inflammatory cell subtypes in asthma","volume":"65","author":"Cowan","year":"2010","journal-title":"Thorax."},{"key":"B97","doi-asserted-by":"publisher","first-page":"66","DOI":"10.12932\/AP0322.32.1.2014","article-title":"Neutrophilic asthma is characterised by increased rhinosinusitis with sleep disturbance and GERD","volume":"32","author":"Simpson","year":"2014","journal-title":"Asian Pac J Allergy Immunol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.it.2017.07.003","article-title":"Neutrophilic inflammation in asthma and association with disease severity","volume":"38","author":"Ray","year":"2017","journal-title":"Trends Immunol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1136\/thorax.57.10.875","article-title":"Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids","volume":"57","author":"Green","year":"2002","journal-title":"Thorax."},{"key":"B100","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","article-title":"Identification of asthma phenotypes using cluster analysis in the severe asthma research program","volume":"181","author":"Moore","year":"2010","journal-title":"Am J Respir Crit Care Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes","volume":"178","author":"Haldar","year":"2008","journal-title":"Am J Respir Crit Care Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/j.jaci.2016.08.048","article-title":"U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics","volume":"139","author":"Lefaudeux","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11882-017-0678-1","article-title":"Phenotype-driven therapeutics in severe asthma","volume":"17","author":"Opina","year":"2017","journal-title":"Curr Allergy Asthma Rep."},{"key":"B104","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1183\/09031936.99.13101599","article-title":"Prednisone-dependent asthma: inflammatory indices in induced sputum","volume":"13","author":"Pizzichini","year":"1999","journal-title":"Eur Respir J."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.jaci.2013.11.042","article-title":"Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data","volume":"133","author":"Wu","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaci.2017.12.1009","article-title":"Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids","volume":"143","author":"Peters","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"e018186","DOI":"10.1136\/bmjopen-2017-018186","article-title":"Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: a retrospective cohort study in a secondary care centre","volume":"7","author":"Demarche","year":"2017","journal-title":"BMJ Open."},{"key":"B108","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/cea.13106","article-title":"Step-down of inhaled corticosteroids in non-eosinophilic asthma: a prospective trial in real life","volume":"48","author":"Demarche","year":"2018","journal-title":"Clin Exp Allergy."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1736934","DOI":"10.1080\/20018525.2020.1736934","article-title":"Clinical characteristics of the BREATHE cohort\u2014a real-life study on patients with asthma and COPD","volume":"7","author":"Backer","year":"2020","journal-title":"Eur Clin Respir J."},{"key":"B110","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/cea.14109","article-title":"Validation and further insight into the International Severe Asthma Registry (ISAR) eosinophil gradient algorithm in the Wessex AsThma CoHort of difficult asthma (WATCH) using historical blood eosinophil counts and induced sputum","volume":"52","author":"Barber","year":"2022","journal-title":"Clin Exp Allergy."},{"key":"B111","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13223-020-00442-0","article-title":"Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma","volume":"16","author":"Henriksen","year":"2020","journal-title":"Allergy Asthma Clin Immunol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","article-title":"Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma","volume":"170","author":"Djukanovi\u0107","year":"2004","journal-title":"Am J Respir Crit Care Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000350852","article-title":"Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma","volume":"161","author":"Takaku","year":"2013","journal-title":"Int Arch Allergy Immunol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1080\/00325481.2017.1321945","article-title":"Predictors of response to therapy with omalizumab in patients with severe allergic asthma\u2014a real life study","volume":"129","author":"Kallieri","year":"2017","journal-title":"Postgrad Med."},{"key":"B115","doi-asserted-by":"publisher","first-page":"e59872","DOI":"10.1371\/journal.pone.0059872","article-title":"Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS ONE."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.5414\/CP202446","article-title":"Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab","volume":"53","author":"Pouliquen","year":"2015","journal-title":"Int J Clin Pharmacol Ther."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S2213-2600(21)00004-7","article-title":"The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study","volume":"9","author":"McDowell","year":"2021","journal-title":"Lancet Respir Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/cea.13601","article-title":"Real-world experience with mepolizumab: does it deliver what it has promised?","volume":"50","author":"Schleich","year":"2020","journal-title":"Clin Exp Allergy."},{"key":"B119","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s11684-017-0565-0","article-title":"Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials","volume":"12","author":"Liu","year":"2018","journal-title":"Front Med."},{"key":"B120","doi-asserted-by":"publisher","first-page":"84","DOI":"10.18176\/jiaci.0385","article-title":"Benralizumab: a new approach for the treatment of severe eosinophilic asthma","volume":"29","author":"D\u00e1vila Gonz\u00e1lez","year":"2019","journal-title":"J Investig Allergol Clin Immunol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000444799","article-title":"A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan","volume":"169","author":"Park","year":"2016","journal-title":"Int Arch Allergy Immunol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med."},{"key":"B123","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12931-019-1065-3","article-title":"Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials","volume":"20","author":"Xiong","year":"2019","journal-title":"Respir Res."},{"key":"B124","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/cea.14112","article-title":"Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta-analysis","volume":"52","author":"Charles","year":"2022","journal-title":"Clin Exp Allergy."},{"key":"B125","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jaci.2014.04.005","article-title":"Lung function decline and variable airway inflammatory pattern: longitudinal analysis of severe asthma","volume":"134","author":"Newby","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4081\/mrm.2020.36","article-title":"Fractional Exhaled Nitric Oxide (FENO) in the management of asthma: a position paper of the Italian Respiratory Society (SIP\/IRS) and Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC)","volume":"15","author":"Heffler","year":"2020","journal-title":"Multidiscip Respir Med."},{"key":"B127","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1164\/rccm.200406-710ST","article-title":"ATS\/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005","volume":"171","year":"2005","journal-title":"Am J Respir Crit Care Med."},{"key":"B128","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1378\/chest.12-0416","article-title":"Normal values and thresholds for the clinical interpretation of exhaled nitric oxide levels in the US general population","volume":"143","author":"See","year":"2013","journal-title":"Chest."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1378\/chest.06-2928","article-title":"Fraction of exhaled nitric oxide at 50 mL\/s: Reference values for adult lifelong never-smokers","volume":"131","author":"Olin","year":"2007","journal-title":"Chest."},{"key":"B130","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12890-017-0456-9","article-title":"Reference values of fractional excretion of exhaled nitric oxide among non-smokers and current smokers","volume":"17","author":"Tor\u00e9n","year":"2017","journal-title":"BMC Pulm Med."},{"key":"B131","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am J Respir Crit Care Med."},{"key":"B132","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1183\/09031936.03.00066903a","article-title":"Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children","volume":"21","author":"Kharitonov","year":"2003","journal-title":"Eur Respir J."},{"key":"B133","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1164\/ajrccm.164.11.2006165","article-title":"Airway inflammation is present during clinical remission of atopic asthma","volume":"164","author":"Van Den Toorn","year":"2001","journal-title":"Am J Respir Crit Care Med."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1111\/j.1365-2222.2005.02314.x","article-title":"The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma","volume":"35","author":"Berry","year":"2005","journal-title":"Clin Exp Allergy."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1183\/09031936.06.00142905","article-title":"Early rise in exhaled nitric oxide and mast cell activation in repeated low-dose allergen challenge","volume":"27","author":"Ihre","year":"2006","journal-title":"Eur Respir J."},{"key":"B136","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1164\/rccm.200610-1427OC","article-title":"The use of exhaled nitric oxide to guide asthma management","volume":"176","author":"Shaw","year":"2007","journal-title":"Am J Respir Crit Care Med."},{"key":"B137","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1164\/ajrccm.157.3.9709064","article-title":"Exhaled nitric oxide correlates with airway hyperresponsiveness in steroid-naive patients with mild asthma","volume":"157","author":"Dupont","year":"1998","journal-title":"Am J Respir Crit Care Med."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/j.rmed.2006.02.019","article-title":"Exhaled nitric oxide as a diagnostic test for asthma in rhinitic patients with asthmatic symptoms","volume":"100","author":"Heffler","year":"2006","journal-title":"Respir Med."},{"key":"B139","unstructured":"2022"},{"key":"B140","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1164\/ajrccm.164.5.2012125","article-title":"The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control","volume":"164","author":"Jones","year":"2001","journal-title":"Am J Respir Crit Care Med."},{"key":"B141","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1136\/thx.2004.023374","article-title":"Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission","volume":"60","author":"Pijnenburg","year":"2005","journal-title":"Thorax."},{"key":"B142","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1183\/09031936.02.00285302","article-title":"Exhaled NO and assessment of anti-inflammatory effects of inhaled steroid: dose-response relationship","volume":"20","author":"Jones","year":"2002","journal-title":"Eur Respir J."},{"key":"B143","volume-title":"The Clinical Utility of Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management. Comparative Effectiveness Review No. 197 (Prepared by the Mayo Clinic Evidence-based Practice Center under Contract No. 290-2015-00013-I)","author":"Wang","year":"2017"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1183\/09031936.00154008","article-title":"Exhaled nitric oxide as a marker of asthma control in smoking patients","volume":"33","author":"Michils","year":"2009","journal-title":"Eur Respir J."},{"key":"B145","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1183\/09031936.00020407","article-title":"Exhaled nitric oxide and asthma control: a longitudinal study in unselected patients","volume":"31","author":"Michils","year":"2008","journal-title":"Eur Respir J."},{"key":"B146","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1016\/j.jaip.2020.06.067","article-title":"Biomarkers of type 2 airway inflammation as predictors of loss of asthma control during step-down therapy for well-controlled disease: the Long-Acting Beta-Agonist Step-Down Study (LASST)","volume":"8","author":"Bose","year":"2020","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B147","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1056\/NEJMoa043596","article-title":"Use of exhaled nitric oxide measurements to guide treatment in chronic asthma","volume":"352","author":"Smith","year":"2005","journal-title":"N Engl J Med."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19820","article-title":"Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath","volume":"19","author":"Harnan","year":"2015","journal-title":"Health Technol Assess."},{"key":"B149","doi-asserted-by":"publisher","first-page":"CD011440","DOI":"10.1002\/14651858.CD011440.pub2","article-title":"Exhaled nitric oxide levels to guide treatment for adults with asthma","volume":"9","author":"Petsky","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"B150","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1164\/rccm.201806-1182OC","article-title":"Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma","volume":"199","author":"Heaney","year":"2019","journal-title":"Am J Respir Crit Care Med."},{"key":"B151","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13601-019-0282-7","article-title":"Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations","volume":"9","author":"Price","year":"2019","journal-title":"Clin Transl Allergy."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1602135","DOI":"10.1183\/13993003.02135-2016","article-title":"T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED","volume":"49","author":"Kuo","year":"2017","journal-title":"Eur Respir J."},{"key":"B153","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1164\/rccm.201512-2452OC","article-title":"A Transcriptome-driven analysis of epithelial brushings and bronchial biopsies to define asthma phenotypes in U-BIOPRED","volume":"195","author":"Kuo","year":"2017","journal-title":"Am J Respir Crit Care Med."},{"key":"B154","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","article-title":"Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry","volume":"157","author":"Wang","year":"2020","journal-title":"Chest."},{"key":"B155","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1159\/000524498","article-title":"Predictors of low and high exhaled nitric oxide values in asthma: a real-world study","volume":"101","author":"Bertolini","year":"2022","journal-title":"Respiration."},{"key":"B156","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med."},{"key":"B157","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.jaci.2017.03.002","article-title":"Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience","volume":"139","author":"Chipps","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"e0183869","DOI":"10.1371\/journal.pone.0183869","article-title":"The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: the ASTERIX Observational study","volume":"12","author":"Bhutani","year":"2017","journal-title":"PLoS ONE."},{"key":"B159","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.pupt.2017.03.004","article-title":"Can the response to Omalizumab be influenced by treatment duration? A real-life study","volume":"44","author":"Sposato","year":"2017","journal-title":"Pulm Pharmacol Ther."},{"key":"B160","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med."},{"key":"B161","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12948-021-00146-9","article-title":"Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis","volume":"19","author":"Canonica","year":"2021","journal-title":"Clin Mol Allergy."},{"key":"B162","doi-asserted-by":"publisher","first-page":"797","DOI":"10.4081\/mrm.2022.797","article-title":"Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management","volume":"17","author":"Carpagnano","year":"2022","journal-title":"Multidiscip Respir Med."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.2147\/JAA.S328988","article-title":"Short-term evaluation of dupilumab effects in patients with severe asthma and nasal polyposis","volume":"14","author":"Pelaia","year":"2021","journal-title":"J Asthma Allergy."},{"key":"B164","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1164\/rccm.201611-2234OC","article-title":"Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma","volume":"196","author":"Kelly","year":"2017","journal-title":"Am J Respir Crit Care Med."},{"key":"B165","doi-asserted-by":"publisher","first-page":"17534666211009398","DOI":"10.1177\/17534666211009398","article-title":"Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study","volume":"15","author":"Detoraki","year":"2021","journal-title":"Ther Adv Respir Dis."},{"key":"B166","doi-asserted-by":"publisher","first-page":"101899","DOI":"10.1016\/j.pupt.2020.101899","article-title":"Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life","volume":"61","author":"Sposato","year":"2020","journal-title":"Pulm Pharmacol Ther."},{"key":"B167","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1111\/all.13937","article-title":"Efficacy of mepolizumab in patients with previous omalizumab treatment failure: real-life observation","volume":"74","author":"Bagnasco","year":"2019","journal-title":"Allergy."},{"key":"B168","doi-asserted-by":"publisher","first-page":"1902420","DOI":"10.1183\/13993003.02420-2019","article-title":"Mepolizumab effectiveness and identification of super-responders in severe asthma","volume":"55","author":"Harvey","year":"2020","journal-title":"Eur Respir J."},{"key":"B169","doi-asserted-by":"publisher","first-page":"106080","DOI":"10.1016\/j.rmed.2020.106080","article-title":"Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis","volume":"171","author":"Bagnasco","year":"2020","journal-title":"Respir Med."},{"key":"B170","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1080\/02770903.2021.1963769","article-title":"Blood eosinophil count and FeNO to predict benralizumab effectiveness in real-life severe asthma patients","volume":"59","author":"Watanabe","year":"2022","journal-title":"J Asthma."},{"key":"B171","doi-asserted-by":"publisher","first-page":"047114","DOI":"10.1088\/1752-7155\/9\/4\/047114","article-title":"Extended nitric oxide analysis may improve personalized anti-inflammatory treatment in asthmatic children with intermediate F E NO 50","volume":"9","author":"Thornadtsson","year":"2015","journal-title":"J Breath Res."},{"key":"B172","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/cea.13790","article-title":"Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma","volume":"51","author":"Chen","year":"2021","journal-title":"Clin Exp Allergy."},{"key":"B173","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jaci.2013.05.007","article-title":"What is an \u201ceosinophilic phenotype\u201d of asthma?","volume":"132","author":"Nair","year":"2013","journal-title":"J Allergy Clin Immunol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1164\/rccm.202009-3631CI","article-title":"Severe adult asthmas: integrating clinical features, biology, and therapeutics to improve outcomes","volume":"203","author":"Wenzel","year":"2021","journal-title":"Am J Respir Crit Care Med."},{"key":"B175","unstructured":"Biomarkers in Asthma34251\n            RicciardoloFLM\n            CarrieroV\n            BertoliniF\n          Encyclopedia of Respiratory Medicine2022"},{"key":"B176","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med."},{"key":"B177","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0091-6749(97)70195-7","article-title":"Eosinophils, mast cells, and basophils in induced sputum from patients with seasonal allergic rhinitis and perennial asthma: Relationship to methacholine responsiveness","volume":"100","author":"Foresi","year":"1997","journal-title":"J Allergy Clin Immunol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.969243\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T04:58:18Z","timestamp":1665377898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.969243\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":177,"alternative-id":["10.3389\/fmed.2022.969243"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.969243","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,10]]},"article-number":"969243"}}